November 2015

One of the most widely talked about trends in healthcare is precision medicine, which uses detailed genetic information about a patient’s cancer to more precisely treat the disease, effectively targeting the tumor. This heightened awareness raises an important question: are precision medicine and pathways compatible?

Site neutrality sounds like something from the Cold War—a zone on a bridge between two ideologically different countries, for instance. In oncology, it’s something completely different.

The advent of ICD-10 turned out to be a lot like the Y2K scare of 15 years ago when a structural programming characteristic dating from the dawn of the computer age seemed likely to cause the digital world to grind to a halt.

The NCCN announced a new series of cancer regimen guidelines that incorporate cost considerations to aid and facilitate broader discussion between physicians and patients about treatment.

The jury is still out on whether use of an algorithm to help classify risk levels in ovarian cancer can improve overall survival but a company is already marketing the system in Britain and plans to bring it to the United States before the end of the year.